IDEXX Laboratories, Inc. $IDXX Shares Sold by Marks Group Wealth Management Inc

Marks Group Wealth Management Inc reduced its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 21.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 7,972 shares of the company’s stock after selling 2,129 shares during the period. Marks Group Wealth Management Inc’s holdings in IDEXX Laboratories were worth $5,393,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Virtus Advisers LLC purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter worth about $26,000. Park Place Capital Corp purchased a new stake in shares of IDEXX Laboratories during the 4th quarter worth about $29,000. WealthCollab LLC purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter worth about $30,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter worth about $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC boosted its stake in shares of IDEXX Laboratories by 58.8% during the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after acquiring an additional 20 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Down 0.2%

IDXX opened at $561.17 on Tuesday. IDEXX Laboratories, Inc. has a twelve month low of $506.91 and a twelve month high of $769.98. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The company has a 50-day moving average price of $562.81 and a 200 day moving average price of $631.11. The company has a market cap of $44.27 billion, a PE ratio of 41.32, a price-to-earnings-growth ratio of 3.08 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the prior year, the firm earned $2.91 EPS. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IDXX has been the topic of several recent analyst reports. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Stifel Nicolaus lowered their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. UBS Group lowered their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Citigroup initiated coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price on the stock. Finally, Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Seven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.